ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Average Price Target of $7.60

ProQR Therapeutics N.V. (NASDAQ:PRQR) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $7.60.

Several research firms have recently issued reports on PRQR. Weiss Ratings raised ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Bank of America initiated coverage on ProQR Therapeutics in a report on Thursday, August 20th. They set a “buy” rating and a $8.00 price target on the stock. JonesTrading cut their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Chardan Capital restated a “buy” rating and issued a $3.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Finally, HC Wainwright decreased their target price on ProQR Therapeutics to $8.00 and set a “buy” rating for the company in a research report on Thursday, October 1st.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PRQR. RFG Advisory LLC grew its holdings in shares of ProQR Therapeutics by 236.8% during the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 45,000 shares during the last quarter. Axiom Investment Management LLC bought a new stake in ProQR Therapeutics in the first quarter worth $53,000. Walleye Capital LLC lifted its stake in ProQR Therapeutics by 2.7% in the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after purchasing an additional 15,744 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 11,186 shares during the period. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.33 on Friday. The stock’s fifty day simple moving average is $1.85 and its two-hundred day simple moving average is $1.75. ProQR Therapeutics has a 1-year low of $1.30 and a 1-year high of $3.00.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.56 million. As a group, research analysts expect that ProQR Therapeutics will post -0.45 earnings per share for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR’s technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders.